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b McGill International TB Center, Montreal, Canada 
c Azhee Akinrin Consulting, Nigeria 
d Centre for Rural Health, School of Nursing and Public Health, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa 
e TB PPM Learning Network, Research Institute of the McGill University Health Centre, Canada 
f Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Canada 
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A B S T R A C T   
The coronavirus disease 2019 (COVID-19) has emerged as a serious threat to global public health, demanding 
urgent action and causing unprecedented worldwide change in a short space of time. This disease has devastated 
economies, infringed on individual freedoms, and taken an unprecedented toll on healthcare systems worldwide. 
As of 1 April 2020, over a million cases of COVID-19 have been reported in 204 countries and territories, 
resulting in more than 51,000 deaths. Yet, against the backdrop of the COVID-19 pandemic, lies an older, 
insidious disease with a much greater mortality. Tuberculosis (TB) is the leading cause of death by a single 
infectious agent and remains a potent threat to millions of people around the world. We discuss the differences 
between the two pandemics at present, consider the potential impact of COVID-19 on TB case management, and 
explore the opportunities that the COVID-19 response presents for advancing TB prevention and control now and 
in future.   
1. Introduction 
The coronavirus disease 2019 (COVID-19) has emerged as a serious 
threat to global public health, demanding urgent action and causing 
unprecedented worldwide change in a short space of time.1 This disease 
has devastated economies, infringed on individual freedoms, and taken 
an unprecedented toll on healthcare systems worldwide. As of October 
09, 2020, about 37 million cases of COVID-19 have been reported in 214 
countries and territories, resulting in over a million deaths.2 Against the 
backdrop of the COVID-19 pandemic lies an older, insidious disease with 
very high mortality. As of 2018, tuberculosis (TB) was the leading cause 
of death by a single infectious agent and remains a potent threat to 
millions of people around the world, with an estimated 10 million 
people infected and 1.5 million deaths.3 With the arrival of COVID-19, 
many of the highest TB-burden countries are grappling with high case-
loads of COVID-19, with severe repercussions on healthcare delivery.4,5 
We discuss the differences between the two pandemics at present, 
consider the potential impact of COVID-19 on TB case management, and 
explore the opportunities that the COVID-19 response presents for 
advancing TB prevention and control now and in future. 
Like COVID-19, TB is spread through minute droplets produced 
through coughing or sneezing.6,7 Unlike COVID-19, TB is a bacterium 
which can progress to active disease soon after exposure or persist in a 
dormant form as latent TB infection.8 The latter makes containment of 
TB particularly tricky, as there is currently no reliable test to determine 
who is most likely to progress to active disease, once infected.9 Despite 
decades of research there is no effective TB vaccine, leaving the prin-
ciples of mitigation for active TB are left to public health measures 
similar to COVID-19, i.e. identify active cases early and trace their 
contacts to test for disease. The reproductive number for TB ranges from 
0.24 in low-burden settings to 4.3 in high-burden settings,10 compared 
to 2–4 for SARS-CoV-2 (the pathogen responsible for COVID-19 disease), 
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making SARS-CoV-2 more transmissible across settings.11 While both 
diseases spread more often in crowded areas, SARS-CoV-2 has been 
shown to transmit from both pre-symptomatic and asymptomatic people 
and is also likely to transmit through fomites, unlike TB (ref). Addi-
tionally, the serial interval, the time between symptom onset of an 
infected person and that of an infected contact, is greater than 4 months 
in TB,11 compared to 3–5 days for COVID-19.12 These differences have 
necessitated a heightened public health response to the COVID-19 
pandemic. 
Other similarities between the two pandemics are demonstrated in 
the way they affect populations. Though TB occurs globally, the ma-
jority of morbidity and mortality occurs in low- and middle-income 
settings, largely due to resource limitations which hamper efforts to 
contain the disease. Africa and Asia account for 85% of the world’s TB 
numbers, and it is the poorest of the poor who are more heavily affected 
due to poorer housing, challenges accessing adequate care, and other 
conditions that hamper the immune system.3 Although TB outbreaks 
occur everywhere, available diagnosis and treatment ensure that people 
in richer countries mostly recover from the disease.3,13 COVID-19, with 
its current rate of spread, lack of treatment and natural immunity, is 
exploiting many of the same health, economic, and social inequities in 
Brazil, India, UK, South Africa, and the United States, that TB has been 
doing for centuries.4,14–16 Even advanced economies in Europe and 
North America have been hit hard and are grappling with outbreaks that 
have caused significant morbidity and mortality, as well as major eco-
nomic and social upheaval.2,17 The inadequate response to COVID-19 in 
many countries (e.g. the United States) highlights the need for political 
leadership with a science-led response, supported by solidarity with 
historically marginalized populations, and within an adequately funded 
public health system.18,19 Worldwide, COVID-19 has exposed gaps in 
health systems and been instrumental in galvanizing the urgency, po-
litical will, action and resources required to aggressively fight the 
pandemic in some countries. However, there have been documented 
inequities in how resources have been deployed and to what populations 
they have been directed.20,21 
Unlike for COVID-19, an effective oral treatment regimen is available 
to treat people with active TB, rendering them non-infectious after less 
than two weeks of treatment.22,23 Preventive therapy is also available, 
and the WHO now recommends its expanded usage beyond people with 
higher risk.24–26 Despite the availability of treatment and preventive 
measures, TB still results in an estimated 1.5 million deaths every year.3 
Although 7 million cases of TB were diagnosed in 2018, an estimated 3 
million were undiagnosed, and about 30% of those diagnosed remained 
untreated.3 
Despite modest progress in global TB prevention and control efforts 
over the last two decades, finding millions of TB cases remains a sig-
nificant challenge. Unless these people are found and successfully 
treated, onward transmission of TB disease cannot be interrupted, and 
the centuries-old epidemic will continue unabated. The latest statistics 
indicate that current efforts are not enough to meet global TB elimina-
tion targets by 2030.3 We also note that the prioritization of resources to 
fight the COVID-19 pandemic and the increased danger of co-infection 
with SARS-CoV-2 to those with TB pose additional threats to TB con-
trol efforts.27 As Pai warns, if concerns are not addressed, COVID-19 
could substantially reverse gains in TB control and worsen the 
epidemic in the coming months.28,29 Early reports from several 
high-burden settings confirm these concerns.28,30,31 Recent modelling 
studies have also quantified excess TB infections and deaths due to 
COVID-19 disruptions in health services, with an estimated 10–16% 
increases in current rates.32–36 
1.1. Potential threats to TB care 
In addition to the far-reaching impacts of COVID-19 on global eco-
nomic, social, financial, political and health systems and the higher risk 
of poor outcomes for those with TB and other health conditions,37,38 a 
lack of comprehensive disaster preparedness will result in specific im-
pacts on TB case-finding and treatment access, outcomes and socio-
economic harms in low-resource settings. 
1.2. Reduced access to healthcare 
In line with World Health Organization recommendations, many 
countries are implementing directives to limit social contact in a bid to 
delay transmission and minimize the impact of COVID-19 on healthcare 
provision. This typically involves compulsory lockdowns, which were 
also enforced in many high-burden TB countries, restriction of move-
ment and disruption of routine activities. Movement restrictions are 
likely to interrupt access to health facilities and disrupt delivery of TB 
services such as community-based active case-finding, contact tracing, 
sputum transportation and distribution of essential commodities, even 
as the potential for community transmission increases.39 Additionally, in 
many settings, TB patients are required to go to a health centre daily for 
directly observed therapy, which would be near impossible in a 
lock-down scenario. Thus, COVID-19 disruptions affect the TB service 
delivery system more than for most other conditions.40,41 
These disruptions could also lead to possible drug stock-outs or ex-
piries of laboratory reagents and other supplies. 
1.3. Diversion of resources away from TB 
Diversion of human resource, funding, and infrastructure towards 
COVID-19 will mean that routine provision of basic healthcare services 
is deprioritized. This can be expected to worsen as the intensity of the 
outbreak overwhelms health systems. Many high-TB burden countries 
are already showing steep increases in COVID-19 cases,42 a trend likely 
to worsen as the pandemic progresses. The need for social distancing 
within health facilities has also meant limitations to the number of pa-
tients who can be seen daily at TB clinics in high-burden settings. In 
addition to being resource-limited, these countries typically have 
higher-risk populations and weaker health systems. A serious outbreak 
could lead to a significant increase in the number of missing TB cases 
and potentially set back recent progress in TB control. 
Increased stigma Stigma and fear of community discrimination asso-
ciated with COVID-19 may deter access to care for patients with cough 
symptoms for the foreseeable future. Consequently, one can anticipate 
delays in care seeking and/or a reduction in the number of people with 
undiagnosed TB presenting to healthcare facilities. Patients may avoid 
seeking TB services for fear of contracting COVID-19. Healthcare 
workers may stigmatize patients with cough for fear of COVID-19, 
especially in settings where personal protective equipment supply is 
inadequate. This will worsen the widely documented stigma that many 
TB patients face, and further delay care-seeking.43–46 
1.4. Catastrophic economic impacts on those at highest risk 
The COVID-19 pandemic has already begun to devastate the global 
economy, with declines in economic activity around the global trans-
portation of goods and services and widespread unemployment from 
lockdowns. The effect will be disproportionately borne by the poor who 
live hand to mouth. With little or no social safety net in many of the 
countries grappling with TB, HIV and malaria epidemics, further 
intensification of predisposing factors such as malnutrition, poverty and 
overcrowding can be expected. These conditions increase the risk of TB 
transmission leading to a spike in TB cases, further compounding the 
diagnostic and treatment access constraints already discussed. 
1.5. TB care lessons and opportunities in the COVID-19 era 
Despite the challenge that the COVID-19 pandemic poses to TB 
control, several opportunities exist which must be leveraged to mitigate 
threats and save lives. These include: 
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1.6. Resource availability and political priority 
The COVID-19 pandemic has galvanized public health actions at 
global and country levels. Many countries, including those with limited 
health budgets, have made resources and infrastructure available at 
record speed in response to or in anticipation of a COVID-19 outbreak. 
The search for a vaccine and treatment for the virus is advancing at an 
extraordinary speed. The response has sometimes resulted in collabo-
rations between governments, donors, private sector, non-government 
organizations, private citizens and other stakeholders. Global and na-
tional public health efforts are receiving a multisectoral response. This is 
an opportunity to also reiterate the TB agenda on national levels but will 
be challenging during the crisis. 
1.7. Galvanizing action to address the social determinants of health 
The pandemic has highlighted historic inequities in health access, 
especially for marginalized populations, which have been the fault lines 
of infectious disease transmission for centuries. Now, perhaps more than 
ever, lies the need to pragmatically address these social determinants of 
health, including poverty, economic, social and gender inequity, and 
malnutrition. Indeed, the COVID-19 response could enable countries to 
build resilient and equitable health systems and address the social de-
terminants of health in tangible ways, and thus achieve a double divi-
dend for epidemic control for TB, COVID-19, and future pandemics. 
1.8. Mitigating the impact on health services 
Even though, by definition, the emergency response to a pandemic 
requires prioritization above routine activities, vertical programming 
must be avoided where possible and care must be taken to avoid 
disabling other essential services. The West Africa Ebola epidemic of 
2014, for example, led to widespread disruption of healthcare services 
including immunization services and a corresponding increase in under- 
five and maternal mortality in Liberia, Sierra Leone and Guinea.9,47 
Similar outcomes can be avoided using several strategies including 
contextualized country plans, fundraising and sustained advocacy, 
trained and appropriately resourced health worker work force, personal 
protective equipment, critical care capacity, diagnostic laboratories, and 
resilient supply chain management systems.28,48,49 
1.9. Opportunities to integrate COVID-19 services with other essential 
services 
The similarities in COVID-19 and TB symptoms, particularly cough 
and fever, present an opportunity for service integration. Identifying 
active TB disease amongst COVID-19 patients and vice versa will be 
imperative to reduce severity of disease. Integration of testing will also 
improve TB case-finding. Cepheid received US FDA emergency use 
authorization in March 2020 for its new Xpert® Xpress COVID-19 
diagnostic that can be processed on the GeneXpert platforms. This 
could fill a crucial diagnostic need, especially in low and middle-income 
countries (LMICs), many of which have an extensive network of Gen-
eXpert machines for TB. In the same vein, the emergency infrastructure 
set up for the purpose of responding to the COVID pandemic can be 
absorbed by TB programs when the present pandemic has been quelled. 
1.10. The role of public health communication in shaping public discourse 
and global action 
Several studies have identified contributory factors for TB underdi-
agnosis, including stigma, poor disease knowledge and perception of 
healthcare services on the patient level, and lack of resources and poor 
knowledge of TB guidelines at the provider level.43,50–52 To mitigate 
these, technological solutions such as e-health and telemedicine have 
been successfully employed in new and innovative ways. Large scale 
mass media campaigns have been launched and social media have been 
exploited in some settings to quell misinformation and educate the 
public, emphasizing trusted scientific sources, although this has been the 
reverse in some countries. There are lessons to be carried forward in TB 
elimination, such as the innovative use of telehealth, text messaging and 
use of social media as well as the engagement of celebrities, journalists 
and popular news sources for the mass proliferation of correct infor-
mation and to unite people experiencing the challenges of social 
distancing. As it could be challenging to disseminate correct public 
health information through social media, there is a need to develop and 
deploy more scientifically based behaviour change communication. 
COVID-19 has disproportionately affected marginalized populations 
in high-income countries to date, and its continuous spread within 
LMICs presents a real and present concern to vulnerable populations, 
even more so for those in high-TB burden countries. The COVID-19 
response to date has demonstrated that, with the right amount of po-
litical will, prioritization and investments, it is possible for the inter-
national community to mobilize resources, accelerate scientific 
discovery, and deploy new public health tools to fight a pandemic. These 
same strategies can thus be employed for TB. Given that most people 
who develop TB can be cured with timely diagnosis and correct treat-
ment, a moral imperative exists to once and for all end the significant yet 
needless morbidity and mortality resulting from TB.53 The momentum 
in global attention, investment and priority to public health must be 
galvanized to end TB and other health threats for all people around the 
world. 
“In the rush to return back to normal, use this time to consider which parts 
of normal are worth rushing back to”. - Lawrence H. Gerstein, Ph.D 
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